On Demand Manufacturing approach
Q-VANT approach supports the vaccine manufacturer for emergency reply, in quickly receiving adjuvant supply for clinical trials, and having the ability to pivot swiftly among vaccine development platforms.
Q-VANT is focused on supplying saponin adjuvants to support the 100 days plan in response to the development of a new vaccine to combat the next pandemic disease.
1
Access to 50 ha of Quillaja plantations (400 million doses/y)
2
Research & Development for saponin adjuvant and api
3
Starting material and veterinary vaccine adjuvant facilities
4
Pure molecule fractionation via liquid chromatography
5
Adjuvant regulatory and Distribution (SPI Pharma)
1
Access to 50 ha of Quillaja plantations (400 million doses/y)
2
Research & Development for saponin adjuvant and api
3
Starting material and veterinary vaccine adjuvant facilities
4
Pure molecule fractionation via liquid chromatography
5
Adjuvant regulatory and Distribution (SPI Pharma)
Instant availability
Q-VANT preparation includes stockpiling saponin adjuvant and holding warm facilities.
Integrated GMP supply chain
Q-Vant’s built an integrated supply chain through partnerships and investors to deliver massively and quickly GMP adjuvants through integrated supply and directs shipment to vaccine manufacturer.
Emergency audit and regulatory filing
Q-VANT Biosciences is prepared for audit and quick regulatory filing for vaccine marketing approval.
